Dermatological advances are not stopping. Learn about the news that this medical specialty brings in 2022.
The Earth has just completed one revolution around the Sun, so it is not surprising that we are looking forward to what this new year holds. Many have their eyes set on the field of dermatology, and we are not only referring to specialists, as more and more people are interested in skin and hair care.
So things, We reveal to you what are the novelties in dermatology of 2022. Having healthy, blemish-free skin doesn’t happen overnight. It requires constant care and the supervision of a dermatologist expert. You might like to check out these options the next time you go on a date.
Topical ruxolitinib approved by the FDA for atopic dermatitis
Thanks to a latest discovery, topical ruxolitinib has emerged as a short-term therapy to treat atopic dermatitis. According to research in adolescents and adults with eczema (mild to moderate), the application of a ruxolitinib cream decreased the redness and itching of the disorder.
Based on these results, the United States Food and Drug Administration (FDA) approved this drug for short-term atopic dermatitis. However, despite the good news, more studies are still needed to verify its long-term safety.
Topical spinosad may cure scabies, says FDA
During the COVID-19 pandemic, observed an increase in cases of familial scabies in Spain and other European countries. Fortunately, FDA confirmed that topical spinosad can treat this disease.
The study behind these findings threw that a single application of topical suspension cured 78% of the children and adults who participated in the trial. However, it should be noted that it has not yet been compared to other preferred medications when treating this disease.
Other dermatological novelties of 2022
This is not the only news the new year has brought us! In addition, how pregnancy affects women with chronic urticaria has been evaluated. In a research with 288 pregnant women with this disease, 51% of the participants reported an improvement, 29% a worsening and 20% did not observe any change.
Lastly, bimekizumab has been linked to hidradenitis suppurativa, a disease characterized by painful sores under the skin. The study published in JAMA Dermatology found that in the first week, 57% of the patients had noticed an improvement. However, more results are still expected.
It might interest you …